-+ 0.00%
-+ 0.00%
-+ 0.00%

Eton Pharma Announces First Patient Dosed In Pilot Clinical Study Assessing Efficacy Of ET-700 For Treatment Of Wilson Disease; Topline Study Results Expected In H2 2026

Benzinga·04/27/2026 10:54:29
Listen to the news

Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the first patient has been dosed in a pilot clinical study assessing the efficacy of ET-700, the Company's proprietary, patent-pending formulation of extended-release zinc acetate under development for the treatment of Wilson disease. Topline study results are expected in the second half of 2026, and if positive, would lead to a pivotal clinical study in early 2027.